Orphan Drugs Market Report, Size, Share, Trends, Growth & Forecast 2020-2025
According to IMARC Group’s latest report, titled “Orphan Drugs Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025,”. Looking forward, IMARC Group expects the global orphan drugs market to exhibit moderate growth during the next five years.
Orphan drugs are used to diagnose, prevent, and treat rare medical disorders. These drugs aim to meet particular public health requirements and generally have a limited production, only for a small group of patients. Orphan drugs help in treating several oncological, metabolic, hematologic, immunologic, infectious, and neurological ailments. These ailments majorly include lymphoma, leukemia, cystic fibrosis, glioma, pancreatic cancer, ovarian cancer, etc.
Request For a Sample Report: https://www.imarcgroup.com/orphan-drugs-market/requestsample
Market Trends
The
high prevalence of cancer and other rare genetic disorders is primarily
driving the need for orphan drugs. Several pharma companies are
focusing on developing new orphan drugs for providing personalized
therapies for patients. Additionally, the higher approval rate of
several pipeline drugs, along with the introduction of numerous
favorable government policies to curb the spread of various infectious
diseases, is also catalyzing the market growth. Moreover, extensive
R&D activities for the development of biological orphan drugs that
can treat cancer and minimize the damage caused to the stem cells are
further expected to drive the market for orphan drugs in the coming
years.
Competitive Landscape:
The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.
Some of these key players include:
- AbbVie Inc.
- Alexion Pharmaceuticals Inc.
- Amgen Inc.
- Biogen Inc.
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche AG (Roche Holding AG)
- Jazz Pharmaceuticals Plc
- Johnson & Johnson
- Merck & Co. Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi S.A.
- Takeda Pharmaceutical Company Limited
- Teva Pharmaceutical Industries Ltd.
The
report has segmented the market on the basis of drug type, disease
type, phase, top selling drug, distribution channel and region.
Breakup by Drug Type:
- Biological
- Non-Biological
Breakup by Disease Type:
- Oncology
- Hematology
- Neurology
- Cardiovascular
- Others
Breakup by Phase:
- Phase I
- Phase II
- Phase III
- Phase IV
Breakup by Top Selling Drugs:
- Revlimid
- Rituxan
- Copaxone
- Opdivo
- Keytruda
- Imbruvica
- Avonex
- Sensipar
- Soliris
- Others
Breakup by Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Stores
- Others
Explore Full Content of Report: https://www.imarcgroup.com/orphan-drugs-market
Breakup by Region:
- North America
- United States
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Key Highlights of the Report
- Market Performance (2014-2019)
- Market Outlook (2020- 2025)
- Porter’s Five Forces Analysis
- Market Drivers and Success Factors
- SWOT Analysis
- Value Chain
- Comprehensive mapping of the competitive landscape
If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
Browse Related Report
https://www.imarcgroup.com/breast-imaging-market
https://www.imarcgroup.com/regenerative-medicine-market
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US:
IMARC Group
30 N Gould St, Ste R
Sheridan, WY 82801, USA
Website: https://www.imarcgroup.com/
Email: sales@imarcgroup.com
USA: +1-631-791-1145
Follow us on twitter: @imarcglobal
Linkedin: https://www.linkedin.com/company/imarc-group
Comments
Post a Comment